Home Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for... UncategorizedWorld News Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - August 25, 2026 179 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENZAMET (ANZUP 1304) study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Repurposing radiotherapy drugs could give immunotherapy a boost November 11, 2022 Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... July 23, 2020 What Caregivers Should Know About End-of-Life Care Issues for People With... September 8, 2022 ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment... August 19, 2026 Load more HOT NEWS What Is Intuitive Eating and How Can It Help During Cancer? Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II... For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT...
